AU2014219075C1 - Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer - Google Patents
Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- AU2014219075C1 AU2014219075C1 AU2014219075A AU2014219075A AU2014219075C1 AU 2014219075 C1 AU2014219075 C1 AU 2014219075C1 AU 2014219075 A AU2014219075 A AU 2014219075A AU 2014219075 A AU2014219075 A AU 2014219075A AU 2014219075 C1 AU2014219075 C1 AU 2014219075C1
- Authority
- AU
- Australia
- Prior art keywords
- chlorophenyl
- bis
- oxo
- morpholinyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CC1CCCC1 Chemical compound *CC1CCCC1 0.000 description 8
- NUCMBIRTYKVEKT-UXHICEINSA-N CC(C)N([C@@H]([C@H](c1cc(C)ccc1)SC1)c(cc2)ccc2Cl)C1=O Chemical compound CC(C)N([C@@H]([C@H](c1cc(C)ccc1)SC1)c(cc2)ccc2Cl)C1=O NUCMBIRTYKVEKT-UXHICEINSA-N 0.000 description 1
- VFQSDHHWNIJHMY-NRSPTQNISA-N CC(C)N([C@@H]([C@H](c1cc(Cl)ccc1)N([C@@H]1CC2)C2=O)c(cc2)ccc2Cl)C1=O Chemical compound CC(C)N([C@@H]([C@H](c1cc(Cl)ccc1)N([C@@H]1CC2)C2=O)c(cc2)ccc2Cl)C1=O VFQSDHHWNIJHMY-NRSPTQNISA-N 0.000 description 1
- WOGCBRIFGUHJCU-HKDCYCCNSA-N CCCC(C(OCC)=O)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1C(c2ccncc2)O)c(cc2)ccc2Cl)C1=O Chemical compound CCCC(C(OCC)=O)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1C(c2ccncc2)O)c(cc2)ccc2Cl)C1=O WOGCBRIFGUHJCU-HKDCYCCNSA-N 0.000 description 1
- VVUXKNRKCZWHMI-ITGKQZKFSA-N CCCCNC([C@@H](CCC)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O)=O Chemical compound CCCCNC([C@@H](CCC)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O)=O VVUXKNRKCZWHMI-ITGKQZKFSA-N 0.000 description 1
- SQBNIFLNZPTGHW-LVVLYVGBSA-N CCCCNC([C@@H](CCC)N([C@@H]([C@H](c1ccc(C)cc1)O[C@H]1Cc(cc2)ccc2C#N)c2ccc(C)cc2)C1=O)=O Chemical compound CCCCNC([C@@H](CCC)N([C@@H]([C@H](c1ccc(C)cc1)O[C@H]1Cc(cc2)ccc2C#N)c2ccc(C)cc2)C1=O)=O SQBNIFLNZPTGHW-LVVLYVGBSA-N 0.000 description 1
- RRRCYDDLRPSTAS-YYGZZXRFSA-N CCC[C@@H](C(O)=O)N([C@H]([C@@H](c(cc1)ccc1Cl)O[C@@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@@H](C(O)=O)N([C@H]([C@@H](c(cc1)ccc1Cl)O[C@@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O RRRCYDDLRPSTAS-YYGZZXRFSA-N 0.000 description 1
- WVZMKSXQNHJRCO-CYRJMILMSA-N CCC[C@H](C#N)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)cc(F)c2I)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](C#N)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)cc(F)c2I)c(cc2)ccc2Cl)C1=O WVZMKSXQNHJRCO-CYRJMILMSA-N 0.000 description 1
- LEOIKUBUEIIJPA-GEEWNISJSA-N CCC[C@H](C(NCC(N)=O)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](C(NCC(N)=O)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc2ccc(C)cc2)c(cc2)ccc2Cl)C1=O LEOIKUBUEIIJPA-GEEWNISJSA-N 0.000 description 1
- XGKWXMMQPUWFBL-IZSFFQSRSA-N CCC[C@H](C(NCCCC(O)=O)=O)N([C@@H]([C@H](c1ccc(C)cc1)O[C@H]1Cc(cc2)ccc2C#N)c2ccc(C)cc2)C1=O Chemical compound CCC[C@H](C(NCCCC(O)=O)=O)N([C@@H]([C@H](c1ccc(C)cc1)O[C@H]1Cc(cc2)ccc2C#N)c2ccc(C)cc2)C1=O XGKWXMMQPUWFBL-IZSFFQSRSA-N 0.000 description 1
- AKVZPAVYTSBNGJ-RAVGUYNFSA-N CCC[C@H](C(O)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)ccc2C#N)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](C(O)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)ccc2C#N)c(cc2)ccc2Cl)C1=O AKVZPAVYTSBNGJ-RAVGUYNFSA-N 0.000 description 1
- WOGCBRIFGUHJCU-XBXAJMJHSA-N CCC[C@H](C(OCC)=O)N(C(C(c(cc1)ccc1Cl)OC1[C@@H](c2ccncc2)O)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](C(OCC)=O)N(C(C(c(cc1)ccc1Cl)OC1[C@@H](c2ccncc2)O)c(cc2)ccc2Cl)C1=O WOGCBRIFGUHJCU-XBXAJMJHSA-N 0.000 description 1
- NKCPCCCFQSYNER-QPXUXIHVSA-N CCC[C@H](C(OCC)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1CC=C)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](C(OCC)=O)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1CC=C)c(cc2)ccc2Cl)C1=O NKCPCCCFQSYNER-QPXUXIHVSA-N 0.000 description 1
- AYQYKRDXHPVENE-RAVGUYNFSA-N CCC[C@H](c1nnn[nH]1)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)cc(F)c2C#N)c(cc2)ccc2Cl)C1=O Chemical compound CCC[C@H](c1nnn[nH]1)N([C@@H]([C@H](c(cc1)ccc1Cl)O[C@H]1Cc(cc2)cc(F)c2C#N)c(cc2)ccc2Cl)C1=O AYQYKRDXHPVENE-RAVGUYNFSA-N 0.000 description 1
- HOPIYEHUEZKLPN-VSKRKVRLSA-N CCOC([C@@H](C1CC1)N([C@@H]([C@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O Chemical compound CCOC([C@@H](C1CC1)N([C@@H]([C@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O HOPIYEHUEZKLPN-VSKRKVRLSA-N 0.000 description 1
- HOPIYEHUEZKLPN-BHDDXSALSA-N CCOC([C@@H](C1CC1)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O Chemical compound CCOC([C@@H](C1CC1)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O HOPIYEHUEZKLPN-BHDDXSALSA-N 0.000 description 1
- GWPRTXFRNRQJLV-MZYLBHOOSA-N CCOC([C@@H](CC1)N([C@H]([C@@H](c(cc2)ccc2Cl)NC(C)C)c2cc(Cl)ccc2)C1=O)=O Chemical compound CCOC([C@@H](CC1)N([C@H]([C@@H](c(cc2)ccc2Cl)NC(C)C)c2cc(Cl)ccc2)C1=O)=O GWPRTXFRNRQJLV-MZYLBHOOSA-N 0.000 description 1
- HOPIYEHUEZKLPN-FSSWDIPSSA-N CCOC([C@H](C1CC1)N([C@@H]([C@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O Chemical compound CCOC([C@H](C1CC1)N([C@@H]([C@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O HOPIYEHUEZKLPN-FSSWDIPSSA-N 0.000 description 1
- HOPIYEHUEZKLPN-FDFHNCONSA-N CCOC([C@H](C1CC1)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O Chemical compound CCOC([C@H](C1CC1)N([C@H]([C@@H](c(cc1)ccc1Cl)OC1)c(cc2)ccc2Cl)C1=O)=O HOPIYEHUEZKLPN-FDFHNCONSA-N 0.000 description 1
- ISEMFQGMTRGCLK-UHFFFAOYSA-N CN(C(C(c(cc1)ccc1Cl)OC1CCN2CCOCC2)c(cc2)ccc2Cl)C1=O Chemical compound CN(C(C(c(cc1)ccc1Cl)OC1CCN2CCOCC2)c(cc2)ccc2Cl)C1=O ISEMFQGMTRGCLK-UHFFFAOYSA-N 0.000 description 1
- ISEMFQGMTRGCLK-HWELCPFYSA-N CN(C(C(c(cc1)ccc1Cl)O[C@H]1CCN2CCOCC2)c(cc2)ccc2Cl)C1=O Chemical compound CN(C(C(c(cc1)ccc1Cl)O[C@H]1CCN2CCOCC2)c(cc2)ccc2Cl)C1=O ISEMFQGMTRGCLK-HWELCPFYSA-N 0.000 description 1
- ZUYDNBDMQAEZPD-SJORKVTESA-N CN([C@@H]([C@H](c1cc(Cl)ccc1)OC1)c(cc2)ccc2Cl)C1=O Chemical compound CN([C@@H]([C@H](c1cc(Cl)ccc1)OC1)c(cc2)ccc2Cl)C1=O ZUYDNBDMQAEZPD-SJORKVTESA-N 0.000 description 1
- ZUYDNBDMQAEZPD-BHWOMJMDSA-N CN([C@H](C(c1cccc(Cl)c1)OC1)c(cc2)ccc2Cl)C1=O Chemical compound CN([C@H](C(c1cccc(Cl)c1)OC1)c(cc2)ccc2Cl)C1=O ZUYDNBDMQAEZPD-BHWOMJMDSA-N 0.000 description 1
- ZOHISOPDHUSNHZ-IARZGTGTSA-N CS(c1ccc(C[C@@H](C(N([C@@H]2c(cc3)ccc3Cl)c3cccnc3)=O)O[C@H]2c(cc2)ccc2Cl)cc1)(=O)=O Chemical compound CS(c1ccc(C[C@@H](C(N([C@@H]2c(cc3)ccc3Cl)c3cccnc3)=O)O[C@H]2c(cc2)ccc2Cl)cc1)(=O)=O ZOHISOPDHUSNHZ-IARZGTGTSA-N 0.000 description 1
- FCZOSVVQRLSJLT-ZRBLBEILSA-N Cc1ccc(C[C@@H](C(N[C@@H]2c(cc3)ccc3Cl)=O)O[C@H]2c(cc2)ccc2Cl)cc1 Chemical compound Cc1ccc(C[C@@H](C(N[C@@H]2c(cc3)ccc3Cl)=O)O[C@H]2c(cc2)ccc2Cl)cc1 FCZOSVVQRLSJLT-ZRBLBEILSA-N 0.000 description 1
- MVLHGARKJUDJMB-ALNDXVPUSA-N Cc1ccc([C@@H]([C@@H](c2cccc(Cl)c2)O[C@@H]2CC(O)=O)N([C@H](c3ccccc3)C#N)C2=O)cc1 Chemical compound Cc1ccc([C@@H]([C@@H](c2cccc(Cl)c2)O[C@@H]2CC(O)=O)N([C@H](c3ccccc3)C#N)C2=O)cc1 MVLHGARKJUDJMB-ALNDXVPUSA-N 0.000 description 1
- MVLHGARKJUDJMB-RYJQUDHMSA-N Cc1ccc([C@H]([C@H](c2cc(Cl)ccc2)O[C@H]2CC(O)=O)N([C@@H](c3ccccc3)C#N)C2=O)cc1 Chemical compound Cc1ccc([C@H]([C@H](c2cc(Cl)ccc2)O[C@H]2CC(O)=O)N([C@@H](c3ccccc3)C#N)C2=O)cc1 MVLHGARKJUDJMB-RYJQUDHMSA-N 0.000 description 1
- KYKGZUUEACPREF-GNLZIIPMSA-N Cc1nnc([C@@H](C2CC2)N([C@H]([C@@H](c2cccc(Cl)c2)O[C@@H]2CC(O)=O)c3ccc(C)cc3)C2=O)[o]1 Chemical compound Cc1nnc([C@@H](C2CC2)N([C@H]([C@@H](c2cccc(Cl)c2)O[C@@H]2CC(O)=O)c3ccc(C)cc3)C2=O)[o]1 KYKGZUUEACPREF-GNLZIIPMSA-N 0.000 description 1
- KYKGZUUEACPREF-IGABQKFOSA-N Cc1nnc([C@H](C2CC2)N([C@@H]([C@H](c2cc(Cl)ccc2)O[C@H]2CC(O)=O)c3ccc(C)cc3)C2=O)[o]1 Chemical compound Cc1nnc([C@H](C2CC2)N([C@@H]([C@H](c2cc(Cl)ccc2)O[C@H]2CC(O)=O)c3ccc(C)cc3)C2=O)[o]1 KYKGZUUEACPREF-IGABQKFOSA-N 0.000 description 1
- SPTXRMDRZMEGIK-UHFFFAOYSA-N O=C(C(Cc(cc1)ccc1F)OC1c(c(-c2c3)c4)ccc4Cl)NC1c2ccc3Cl Chemical compound O=C(C(Cc(cc1)ccc1F)OC1c(c(-c2c3)c4)ccc4Cl)NC1c2ccc3Cl SPTXRMDRZMEGIK-UHFFFAOYSA-N 0.000 description 1
- XMNWENGUOFYBBL-GDRMZMBQSA-N O=C(C(Cc(cc1)ccc1I)O[C@@H]([C@@H]1c(cc2)ccc2Cl)c(cc2)ccc2Cl)N1c1cccnc1 Chemical compound O=C(C(Cc(cc1)ccc1I)O[C@@H]([C@@H]1c(cc2)ccc2Cl)c(cc2)ccc2Cl)N1c1cccnc1 XMNWENGUOFYBBL-GDRMZMBQSA-N 0.000 description 1
- XMNWENGUOFYBBL-VJGNERBWSA-N O=C([C@H](Cc(cc1)ccc1I)O[C@H]([C@H]1c(cc2)ccc2Cl)c(cc2)ccc2Cl)N1c1cccnc1 Chemical compound O=C([C@H](Cc(cc1)ccc1I)O[C@H]([C@H]1c(cc2)ccc2Cl)c(cc2)ccc2Cl)N1c1cccnc1 XMNWENGUOFYBBL-VJGNERBWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766625P | 2013-02-19 | 2013-02-19 | |
| US61/766,625 | 2013-02-19 | ||
| PCT/US2014/016971 WO2014130470A1 (en) | 2013-02-19 | 2014-02-18 | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014219075A1 AU2014219075A1 (en) | 2015-08-27 |
| AU2014219075B2 AU2014219075B2 (en) | 2018-03-01 |
| AU2014219075C1 true AU2014219075C1 (en) | 2018-09-06 |
Family
ID=50236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014219075A Active AU2014219075C1 (en) | 2013-02-19 | 2014-02-18 | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160002185A1 (https=) |
| EP (1) | EP2958902B1 (https=) |
| JP (1) | JP6417338B2 (https=) |
| AU (1) | AU2014219075C1 (https=) |
| CA (1) | CA2901696C (https=) |
| MX (1) | MX362896B (https=) |
| WO (1) | WO2014130470A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| HRP20220718T1 (hr) | 2013-11-11 | 2022-09-30 | Amgen Inc. | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049250A1 (en) * | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3246148A1 (de) * | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| EA012181B1 (ru) | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| EA017389B1 (ru) | 2007-03-23 | 2012-12-28 | Амген Инк. | Гетероциклические соединения и их применение |
| WO2008118454A2 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
| RS53151B (sr) | 2007-03-23 | 2014-06-30 | Amgen Inc. | 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) |
| CN101809002B (zh) * | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| US8389533B2 (en) | 2008-04-07 | 2013-03-05 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| AU2010216239B2 (en) | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| MX2011012037A (es) | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
| WO2010151735A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP2445902A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | Heterocyclic compounds and their uses as inhibitors of pi3k activity |
| CN102625799A (zh) | 2009-06-25 | 2012-08-01 | 安姆根有限公司 | 杂环化合物及其用途 |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
-
2014
- 2014-02-18 US US14/768,529 patent/US20160002185A1/en not_active Abandoned
- 2014-02-18 CA CA2901696A patent/CA2901696C/en active Active
- 2014-02-18 AU AU2014219075A patent/AU2014219075C1/en active Active
- 2014-02-18 WO PCT/US2014/016971 patent/WO2014130470A1/en not_active Ceased
- 2014-02-18 EP EP14708410.7A patent/EP2958902B1/en active Active
- 2014-02-18 JP JP2015558205A patent/JP6417338B2/ja active Active
- 2014-02-18 MX MX2015010619A patent/MX362896B/es active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049250A1 (en) * | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2901696A1 (en) | 2014-08-28 |
| EP2958902A1 (en) | 2015-12-30 |
| MX2015010619A (es) | 2016-04-19 |
| AU2014219075B2 (en) | 2018-03-01 |
| EP2958902B1 (en) | 2017-11-15 |
| CA2901696C (en) | 2021-04-13 |
| JP2016509029A (ja) | 2016-03-24 |
| MX362896B (es) | 2019-02-22 |
| AU2014219075A1 (en) | 2015-08-27 |
| JP6417338B2 (ja) | 2018-11-07 |
| US20160002185A1 (en) | 2016-01-07 |
| WO2014130470A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2906538C (en) | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer | |
| AU2014219075C1 (en) | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | |
| US9376425B2 (en) | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | |
| CA2799972C (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| US11407721B2 (en) | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2018 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2018 |
|
| FGA | Letters patent sealed or granted (standard patent) |